Has The Recent Pullback In Alnylam Pharmaceuticals (ALNY) Opened A Valuation Opportunity?

Simply Wall St.

Jan 31

Wondering if Alnylam Pharmaceuticals at around US$346 is offering you fair value or asking too much? This article walks through the key numbers that matter for investors focused on price versus value....

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2607078707"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607078707\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607078707?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-31 04:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607078707","market":"us","top_or_hot":-1,"title":"Has The Recent Pullback In Alnylam Pharmaceuticals (ALNY) Opened A Valuation Opportunity?","media":"Simply Wall St.","content":"<div>\n<p>Wondering if Alnylam Pharmaceuticals at around US$346 is offering you fair value or asking too much? This article walks through the key numbers that matter for investors focused on price versus value....</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/has-the-recent-pullback-in-alnylam-pharmaceuticals-alny-open\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Has The Recent Pullback In Alnylam Pharmaceuticals (ALNY) Opened A Valuation Opportunity?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHas The Recent Pullback In Alnylam Pharmaceuticals (ALNY) Opened A Valuation Opportunity?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-31 04:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/has-the-recent-pullback-in-alnylam-pharmaceuticals-alny-open><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wondering if Alnylam Pharmaceuticals at around US$346 is offering you fair value or asking too much? This article walks through the key numbers that matter for investors focused on price versus value....</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/has-the-recent-pullback-in-alnylam-pharmaceuticals-alny-open\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/has-the-recent-pullback-in-alnylam-pharmaceuticals-alny-open","article_id":"2607078707","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/has-the-recent-pullback-in-alnylam-pharmaceuticals-alny-open","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2607078707","pubTimestamp":1769805113,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Wondering if Alnylam Pharmaceuticals at around US$346 is offering you fair value or asking too much? This article walks through the key numbers that matter for investors focused on price versus value.\nThe stock has pulled back recently, with a 6.3% decline over the last 7 days and a 12.7% decline over the past 30 days, although the 1 year return sits at 25.1% and the 5 year return at 119.6%.\nRecent attention on Alnylam Pharmaceuticals has centred on its broader pipeline and commercial...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4548":"巴美列捷福持仓","BK4139":"生物科技","ALNY":"阿尔尼拉姆制药公司","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU0882574055.USD":"富达全球健康医疗A ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC"},"translate_title":"Alnylam Pharmaceuticals(ALNY)最近的回调是否带来了估值机会？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":1.5,"DCF":1},"content_text":"Wondering if Alnylam Pharmaceuticals at around US$346 is offering you fair value or asking too much? This article walks through the key numbers that matter for investors focused on price versus value. The stock has pulled back recently, with a 6.3% decline over the last 7 days and a 12.7% decline over the past 30 days, although the 1 year return sits at 25.1% and the 5 year return at 119.6%. Recent attention on Alnylam Pharmaceuticals has centred on its broader pipeline and commercial profile, which continues to shape how investors think about its long term prospects and risk profile. This background helps frame why the recent share price moves may not fully capture what the business could be worth on different valuation measures. On Simply Wall St's valuation checks, Alnylam Pharmaceuticals currently scores 4 out of 6. Next, we will walk through the main valuation approaches behind that score, before finishing with a way to look at valuation that can give you a clearer, big picture view of the stock.  Alnylam Pharmaceuticals delivered 25.1% returns over the last year. See how this stacks up to the rest of the Biotechs industry. AdvertisementApproach 1: Alnylam Pharmaceuticals Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and discounting them back to a single present value figure. For Alnylam Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow is about $195.7 million. Analysts provide estimates out to 2026, then the model extrapolates further, with projected free cash flow of $4.45b in 2030. These longer term projections and their discounted values are combined to arrive at an estimated intrinsic value per share of about $867.28. Set against a recent share price around $346, this DCF output implies the stock is about 60.0% below that intrinsic value. Within the assumptions of this model, the shares screen as undervalued. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Alnylam Pharmaceuticals is undervalued by 60.0%. Track this in your watchlist or portfolio, or discover 869 more undervalued stocks based on cash flows. ALNY Discounted Cash Flow as at Jan 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Alnylam Pharmaceuticals. Approach 2: Alnylam Pharmaceuticals Price vs Sales For companies where current earnings are less meaningful, the P/S ratio is often a useful way to think about valuation, because it relates the share price to the revenue base rather than profit, which can swing with investment and accounting choices. What counts as a normal P/S ratio depends on how quickly investors expect revenue to grow and how much risk they see in those expectations. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher uncertainty tends to line up with a lower one. Alnylam Pharmaceuticals is trading on a P/S ratio of about 14.27x. That sits above the Biotechs industry average of 11.72x and the peer average of 8.69x. Simply Wall St’s Fair Ratio framework estimates a P/S of 16.29x for Alnylam Pharmaceuticals, based on factors such as its growth profile, margins, industry and market value. Compared with simple peer or industry comparisons, the Fair Ratio aims to be more tailored, as it adjusts for the company’s own growth, risks, profitability, sector and size rather than applying a broad brush benchmark. With the current 14.27x P/S below the 16.29x Fair Ratio, this approach suggests the shares screen as undervalued on a sales multiple basis. Result: UNDERVALUED NasdaqGS:ALNY P/S Ratio as at Jan 2026 P/S ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1418 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Alnylam Pharmaceuticals Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which Simply Wall St makes available on the Community page used by millions of investors. A Narrative is your story about a company, where you spell out what you think is reasonable for future revenue, earnings and margins, then link that to a fair value that can be compared directly to today’s share price. Instead of only looking at raw ratios, you build or select a Narrative that ties Alnylam Pharmaceuticals scientific pipeline, commercial potential and risks to a clear financial forecast. The platform then connects that forecast to an estimated fair value that updates automatically when new earnings or news are added. With Alnylam Pharmaceuticals, for example, one investor might set up a Narrative that points to a much higher fair value, while another uses more cautious assumptions and arrives at a far lower figure. Seeing both side by side helps you decide whether the current price feels attractive or stretched based on your own view. Do you think there's more to the story for Alnylam Pharmaceuticals? Head over to our Community to see what others are saying! NasdaqGS:ALNY 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}